Revealis Joins Cancer Vaccine Race: The Innovative TEIPP Strategy Explained

How TEIPP Vaccines Target Invisible Cancer Cells

Tumors frequently evade T cells by shutting down the machinery that displays warning signs on their surface, specifically by dialing down the activity of TAP proteins. Scientists at Leiden University Medical Center (LUMC) and Oncode Institute discovered that these masked cancer cells inadvertently present an alternative set of targets known as TEIPP epitopes, which stands for T-cell epitopes associated with impaired peptide processing, as reported by European Biotechnology and biotechnews.nl.

By training the immune system to recognize these hidden flags, the biotech startup aims to exploit a notorious evasion tactic as a fatal vulnerability. Most patients do not die from the primary tumor, but from metastasized or recurrent tumors, notes Sjoerd van der Burg, a professor at Leiden University Medical Center and Oncode Accelerator workstream lead for therapeutic vaccines, as cited by biotechnews.nl. Recent developments show that cancer vaccines can work: you can and need to teach the immune system to target cancer, sustain that immune response with checkpoint blockade, and intervene at the right moment. Our vaccine is fundamentally different from the Moderna and Merck approach, but it builds on the same underlying insight. This creates a new therapeutic opportunity.

Clinical Trial Results and Safety Data in Lung Cancer

Researchers put this exact concept to the test in a first-in-human Phase 1/2 clinical trial involving 26 patients with metastatic non-small cell lung cancer whose illness had kept advancing despite checkpoint inhibitor treatment, according to European Biotechnology. The prototype vaccine, named TEIPP24, delivered a synthetic peptide derived from LRPAP1, though it was strictly limited to patients carrying the HLA-A*0201 marker, as detailed by European Biotechnology and biotechnews.nl.

More than 80% of evaluable participants developed TEIPP-specific immune responses after getting the shots, proving the biological concept worked in humans, according to European Biotechnology and biotechnews.nl. However, that immune activation did not immediately translate into sweeping tumor shrinkage. Out of 24 radiologically evaluable patients, exactly one achieved a partial response, eight hit stable disease, and two showed mixed responses, while median progression-free survival sat at just 2.1 months, with 25 of the 26 enrolled patients eventually progressing, as reported by European Biotechnology.

Pipeline Expansion and the Dark Proteome

To overcome the limitations of a single-target approach, Revealis plans to formulate a next-generation vaccine packed with multiple TEIPP peptides, which should broaden immune engagement and open the door to a larger patient population, according to European Biotechnology and biotechnews.nl. The Oncode Accelerator—a Dutch public-private consortium established in 2023 to de-risk preclinical drug development—is actively aiding the hunt for new targets, including antigens pulled from the mysterious dark proteome, as noted by European Biotechnology.

Financial backing for this foundational phase comes from Oncode BV, which is the venture arm of the Oncode Institute, alongside two family offices that chipped in for pre-seed funding, according to European Biotechnology and biotechnews.nl. We now have not only a strong scientific concept, but also clinical proof-of-concept, the company stated in an announcement highlighted by biotechnews.nl. Revealis Biotherapeutics brings together the expertise, financing and development strategy needed to take these results to the next stage towards an actual cancer vaccine. Additional capital and strategic partners will be mandatory as the pipeline inches toward subsequent clinical trials.

Personalized Neoantigens Versus Immune Escape Targeting

This rollout arrives as therapeutic cancer vaccines enjoy a massive resurgence in the oncology world, largely spurred by late-stage wins for Moderna and MSD’s personalized mRNA vaccine combined with pembrolizumab in high-risk melanoma, according to European Biotechnology and biotechnews.nl. While competitors manufacture bespoke vaccines tailored to the specific mutations inside each individual patient’s tumor, Revealis is charting a different course by targeting a shared vulnerability that emerges whenever tumors alter their antigen-presentation machinery, as reported by European Biotechnology.